Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T13:46:14.365Z.
Calculation as of: 2026-10-06T13:46:14.365Z.
Quote observation: 2026-10-06T13:45:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47fe9b5a4b5325aa2b63eefeab4e4f99d65252ab4bc117be38c834a5b01498bd
EARNINGS YIELD
N/A
Market Cap
$115.66M
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.58M
Earnings Yield
N/A
TTM Avg
9.36%
3Y Avg
9.36%
5Y Avg
9.36%
Market Cap
$110.75M
Earnings Yield
N/A
TTM Avg
26.36%
3Y Avg
26.36%
5Y Avg
26.36%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | $114.71M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.66M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.58M | N/A | 9.36% | 9.36% | 9.36% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $116.30M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $117.03M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $111.89M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.84M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.75M | N/A | 26.36% | 26.36% | 26.36% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.52M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
